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Abstract
Gastric cancer (GC) is a common cause of cancer-related deaths in the world. In addition to the patient’s clinical history and 
clinical examination, nuclear medicine tools are required for diagnosis. [18F]FDG PET/CT has been commonly used for cancer 
patients for staging, restaging, evaluation of treatment response. This study aimed to review the current literature on the role 
of [18F]FDG PET/CT for GC management.
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Introduction 
Gastric cancer (GC) is a common neoplasm and GC is the 
third most widespread cause of cancer-related deaths worldwide. 
GC generally affects men higher than women. Various factors such 
as Helicobacter Pylori, bad diet habits and smoking give rise to 
GC [1]. GC is a cancer type usually diagnosed at an advanced 
stage. Patient history, physical examination, endoscopy and biopsy 
is essential for the diagnosis of this disease. Diagnostic imaging 
modalities including endoscopic ultrasound (EUS), computed to-
mography (CT), magnetic resonance imaging (MRI) and positron 
emission tomography/computed tomography (PET/CT) are used 
for the initial evaluation of GC. Fluorine-18 fluoro-2-deoxy-D-glu-
cose ([18F]FDG) PET/CT is recommended if there is no evidence 
for metastasis and if clinically indicated according to National 
Comprehensive Cancer Network (NCCN) guidelines. PET/CT might 
be useful for the evaluation of therapy response before surgery, 
recurrence and determination of occult metastatic tumour [2]. 
In this review article, the role of [18F]FDG PET/CT for GC manage-
ment is evaluated in light of the current literature.
Detection of primary tumours  
and prediction of prognosis
A cancer screening programme for detecting GC found that 
FDG-PET had 37.9% sensitivity. Furthermore, FDG-PET had lower 
sensitivity than endoscopy. FDG-PET demonstrated early-stage GC 
in some cases. However, many of them were shown with a com-
bination of endoscopy. Therefore, the combination of endoscopy 
was helpful for the detection of tumours at an early stage [3].
Dual time point imaging (DTPI) [18F]PET/CT was analysed to 
differentiate malignant and benign disease of GC patients (n = 74) 
with focal increased gastric uptake on imaging. The maximum 
standardized uptake value (SUVmax) of the early PET/CT imag-
ing was 5.0 ± 1.4, the SUVmax of the delayed PET/CT imaging 
was 5.9 ± 2.7. The study concluded that DTPI can play an important 
role in differentiating malignant disease from the benign gastric 
disease [4]. 
The utility of [18F]FDG PET/CT was investigated for detecting 
primary GC in suspected GC patients (n = 68). After fasting whole-
body PET/CT imaging, the patients drank a measured amount of 
milk with Diatrizoate Meglumine. Local gastric PET/CT imaging 
was also performed. Whole-body PET/CT had 92.9% sensitivity, 
75.0% specificity, 94.5% PPV, and 69.0% negative predictive value 
(NPV) for detecting primary tumour. Local gastric PET/CT had 
91.1% sensitivity, 91.7% specificity, 98.1% PPV, and 68.8% NPV. 
The mean ratio of the tumour’s SUVmax/the adjacent gastric wall 
SUVmax was significantly increased with local gastric PET/CT. 
It was concluded that gastric distention might be useful for tumour 
visibility. However, gastric distention may not significantly improve 
diagnostic accuracy [5]. 
[18F]FDG uptake was investigated for the detection of regional 
lymph nodes (LNs) in preoperative GC patients (n = 156). Tumour 
size (≥ 3 cm) and LN metastasis were significantly associated 
with [18F]FDG uptake in LN. When the SUVmax of the primary tu-
mour > 3.75, PET/CT had 73.5% sensitivity and 74.5% specificity 
for the detection of LN metastasis. While the SUVmax of the pri-
mary tumour > 4.35 and FDG uptake of LN was positive, PET/CT 
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had 58.8% sensitivity and 91.6% specificity for the prediction of 
non-curative surgery [6]. 
Histopathologic characteristics of primary GC affect the FDG 
uptake and tumour detection rate on FDG PET/CT. In a study of 50 
patients with preoperative locally advanced gastric adenocarcino-
ma (GA), FDG uptake of the primary tumour was investigated. Re-
sults were correlated with histopathologically. The poorly cohesive 
type according to the WHO classification, diffuse type according to 
the Lauren classification and infiltrative type according to the Ming 
classification had low FDG uptake in these patients. Therefore, the 
correlation between FDG uptake and histopathologic characteris-
tics might be useful for FDG PET/CT imaging in GC patients [7]. 
Diagnostic accuracy of whole-body [18F]FDG PET/CT and re-
gional [18F]FDG PET/CT after water gastric inflation was assessed 
in preoperative GC patients (n = 44). The sensitivity of whole-body 
PET/CT (50%) was augmented by regional PET/CT (75%) for primary 
tumour detection. Furthermore, the sensitivity of whole-body PET/CT 
(24.6%) for LN metastasis was significantly increased by regional 
PET/CT (36.1%). Regional PET/CT can be used to improve FDG 
uptake in GC patients [8]. 
The utility of [18F]FDG PET/CT was evaluated for progres-
sion-free survival (PFS) before therapy in GC patients (n = 321). 
The Low SUVmax group (≤ 5.74) had a longer mean PFS than that 
of the high SUVmax group (> 5.74). Stage, depth of tumour inva-
sion, presence of LN metastasis and SUVmax (> 5.74 vs ≤ 5.74) 
were associated with recurrence. High SUVmax (> 5.74) and high 
metabolic tumour volume (MTV) (> 16.42) were poor prognostic 
factors for PFS [9]. 
The prognostic role of baseline and interim [18F]FDG PET/CT 
during chemotherapy was examined in patients (n = 44) with 
recurrent/metastatic advanced gastric cancer (AGC). Initial and 
change of metabolic parameters (MP)-MTV, tumour lesion glycoly-
sis (TLG) and SUVmax and SUVmean were measured. Decreased 
percentage of SUVmax and SUVmean on interim PET/CT and initial 
values of volumetric parameters (MTV and TLG) were significant 
predicting factors for chemotherapy response. Furthermore, the 
decreased percentage values of metabolic parameters as well 
as maximum and mean SUV were important prognostic factors for 
overall survival (OS) and PFS [10]. 
The prediction of prognosis was investigated SUVmax of 
metastatic LNs using [18F]FDG PET/CT in preoperative GC pa-
tients (n = 151). Results were confirmed histologically. Nodal 
SUVmax was an independent prognostic factor for recurrence-free 
survival (RFS) and OS [11]. 
The metabolic affinity of primary tumours or metastatic LNs on 
[18F]FDG PET/CT was studied for the prediction of survival in pa-
tients (n = 168) with AGC. [18F]FDG PET/CT had 73.8% sensitivity 
for the detection of advanced pT ≥ 3 stages. Furthermore, [18F]FDG 
PET/CT had 92.2% specificity for the detection of the advanced pN 
(≥ 2) stage. Data showed that the [18F]FDG affinity of LNs was an in-
dependent prognostic factor for RFS [12]. 
TNM Staging
Imaging of LN metastasis and accurate staging is needed for 
effective therapy before surgery. However, accurate staging with 
conventional diagnostic imaging modalities such as CT is not 
enough due to its low sensitivity and low specificity. Therefore, 
nuclear medicine imaging methods with high specificity such 
as [18F]FDG PET/CT are necessary to detect metastasis [13].
In a comparative retrospective study, the effect of FDG-PET 
for the staging of Gastric adenocarcinoma (GA) was analysed in 
608 patients who had biopsy-proven GA and 207 patients who 
had both CT and FDG-PET. FDG-PET identified primary tumour 
(PT) (125 vs 120) more than CT alone. Furthermore, FDG detected 
distant lymph node disease (DLN) (41 vs 25) more than CT alone. In 
addition, FDG-PET up-staged 31 patients and down-staged 17 pa-
tients. PET/CT was more helpful than CT for the staging of GA [14]. 
In another comparative study, FDG PET/CT was researched 
in 97 histologically proven GC patients. It was reported that FDG 
uptake in both tumour and LN were related to poor OS. In contrast to 
FDG PET/CT, lymphadenomegaly was not related to OS on CT. FDG 
PET/CT had more prognostic importance than CT for staging [15]. 
A study (n = 90) reported that FDG PET/CT had 78.9% sen-
sitivity for detecting primary GC. It was noted that T3/T4 disease 
had higher SUVmax than T1/T2 disease (9.0 vs 3.8) on PET/CT 
imaging. The SUVmax of the primary tumour was associated with 
tumour size. FDG-PET/CT had 64.5% sensitivity, 85.7% specificity, 
71.1% accuracy, 90.9% PPV, and 52.2 % NPV for evaluation of local 
LN metastasis [16]. 
[18F]FDG PET/CT was examined in non-junctional GC pa-
tients (n = 279). 80.6% of the primary tumour was FDG-avid. PET/CT 
detected 7% of patients that could not be shown with other imaging 
methods. For metastatic disease, PET/CT had 49.3% sensitivity, 
97.1% specificity, 85.0% PPV, 85.4% NPV. This recent study reported 
that PET/CT should be used for staging and it should have a place 
in guidelines [17].
[18F]FDG PET/CT was analysed to image metabolically positive 
lymph nodes (MPLN) in patients (n = 50) with locally AGC. The 
numbers of MPLN were associated with the numbers of histolog-
ically positive LNs . The numbers of MPLN, PET/CT positive LN, 
SUVmax of LN (> 2.8), TNM stage were correlated with OS. There-
fore, the number of MPLN is an important parameter for predicting 
the prognosis of locally AGC [18]. 
The relationship between FDG uptake in the primary tu-
mour/LNs and clinicopathological factors, especially pStage III/IV 
were evaluated in AGC patients (n = 117). FDG uptake in primary 
tumour and LNs were related with pStage III/IV. FDG PET/CT had 
22.7% sensitivity, 90.5% specificity for LN metastasis. FDG PET/CT 
had 80.4% sensitivity for the detection of pStage III/IV disease. 
As a result, PET/CT was a helpful modality for the evaluation of 
pStage III/IV [13]. 
In a retrospective study (n = 45), the role of F-FDG PET/CT 
for staging GC was compared with contrast-enhanced computed 
tomography (CECT). There was no significant statistical difference 
found between PET parameters and histotype, grading, and site 
of the gastric lesion. FDG PET/CT had higher specificity for both 
LN and distant metastasis [19]. 
In another retrospective study, clinicopathologic parame-
ters that were related to [18F]FDG avidity was examined. Large 
tumour size, non-signet ring cell carcinoma type, and glucose 
transporter 1-positive expression on immunohistochemistry were 
strong predictive factors about [18F]FDG avidity. PET scoring sys-
tem which was developed from these parameters detected [18F]
FDG-avid cancer and it had 85% sensitivity and 71% specificity 
[20]. 
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[18F]FDG PET/CT was compared with CECT in 45 GC pa-
tients for staging. While CECT had 92.11% sensitivity, 57.14% 
specificity; [18F]FDG PET/CT had 81.58% sensitivity, 85.71% spec-
ificity for detection of GC. Whereas CECT had 70.83% sensitivity, 
61.90% specificity; [18F]FDG PET/CT had 58.33% sensitivity, 95.24% 
specificity for LN involvement. While CECT had 80% sensitivity, 
62.86% specificity; [18F]FDG PET/CT had 60% sensitivity, 88.57% 
specificity for distant metastases. The authors stated that [18F]FDG 
PET/CT was helpful for the assessment of GC for the detection of 
the primary tumour, LN and distant metastasis [19]. 
[18F]FDG PET/CT was compared with CECT for staging in lo-
cally AGC patients (n=106). The combination of [18F]FDG PET/CT 
on CECT provided better diagnostic accuracy for imaging of both 
distant LN metastasis and bone metastasis [21]. 
Curability
The utility of FDG PET/CT was evaluated for predicting the cur-
ability of endoscopic submucosal dissection (ESD) for early GC in 
a first research study. EGCs (n = 210) of 199 patients were included. 
The detection rate of early GC with FDG PET/CT was 37.1%. In 
contrast to that, the detection of early GC which were not curable 
by ESD had 79% sensitivity, 91% specificity. It was concluded that 
FDG PET/CT might be a useful method secondary to endoscopy 
for this purpose [22]. 
Detection of recurrent tumours
Diagnostic performance of FDG PET/CT for surveillance was in-
vestigated in asymptomatic 190 GC patients (early GC patients: 
n = 115; AGC patients: n = 75) after surgery. FDG PET/CT had 
good diagnostic performance with 84.2% sensitivity and 87.7% 
specificity [23]. 
In another study, the diagnostic  performance  of [18F]FDG 
PET/CT was evaluated in AGC patients (n = 46) who were asymp-
tomatic and negative on conventional imaging. Final verification 
was performed using clinical follow-up, tumour markers, CT, en-
doscopy and with/without a histopathologic diagnosis. [18F]FDG 
PET/CT had 100% sensitivity, 88.1% specificity, 44.4 % PPV and 
100 % NPV in the patient-based analysis irrespective of the recur-
rence site [24]. 
FDG PET/CT was retrospectively compared with CECT to detect 
gastric carcinoma recurrence. The recurrence group (60 patients) 
and control group were (60 patients) were included. There was no 
significant difference found between these two methods for the 
detection of patient-based overall recurrence. On the other hand, 
CECT had higher sensitivity (96%) than PET/CT (50%) for imaging 
peritoneal carcinomatosis. Furthermore, on pathology-based 
analysis CECT had higher sensitivity (98%) than PET/CT (80%). 
Therefore, CECT might be a primary method for the detection of 
tumour recurrence [25]. 
Diagnostic performance of PET/CT was investigated in 
[18F]FDG-avid AGC patients (n = 368) for detection of recurrence. 
PET had higher sensitivity (81.0%) for [18F]FDG-avid tumours than 
both non-avid tumours and nonanastomosis site recurrences (52.4%). 
PET had high specificity (97.1% and 97.5%) in both groups [26]. 
In a meta-analysis study (828 patients in 14 studies) diag-
nostic accuracy of [18F]FDG PET for detection of GC recurrence 
was examined. On a per-patient basis analysis, [18F]FDG PET had 
85% sensitivity. On per-lesion basis analysis, [18F]FDG PET had 
75% sensitivity [27]. 
The diagnostic utility of FDG PET/CT was evaluated in 279 
patients. The primary tumour was FDG-avid in 80% of patients. 
PET/CT detected unsuspected metastases in 7% of patients. In 
addition, these metastases could not be detected by conventional 
staging without PET/CT in 5% of patients. Patients with FDG-avid 
nodes had an incurable disease. This retrospective study sug-
gested that PET/CT should be considered in international recom-
mendations [17]. 
Therapeutic response evaluation
Investigators evaluated the importance of PET imaging using 
[18F]FDG and [18F]fluoro-3’-deoxy-3’-Lfluorothymidine (FLT) for early 
metabolic response in AGC patients (n = 64) who were treated 
with chemotherapy. PET imaging was performed at baseline and 
14 days after therapy beginning. FDG PET had 70% sensitivity 
and 83% specificity for predicting clinical response. FDG PET had 
58% sensitivity and 100% specificity for predicting disease control 
status using with total uptake value reduction percentage (d-SUV) 
value. In contrast to FDG, the d-SUV value of FLT-PET was not 
useful for both predicting clinical response and disease control 
status. Decreased FDG uptake in liver metastasis helped predict 
both clinical response and disease control status [28]. 
The accuracy of FDG PET/CT to predict early pathologic 
response after neoadjuvant chemotherapy was analysed in 44 
patients with locally advanced GC or esophagogastric junction 
II/III. PET/CT had 90.9% sensitivity, 47.3% specificity, and 63.3% 
accuracy for prediction of response [29]. 
Diffusion-weighted MRI (DW-MRI) and [18F]FDG PET/CT were 
compared for therapy response in patients with locally advanced GA 
(n = 17). Apparent diffusion coefficient (ADC) value and SUVmean 
corrected for partial volume effect were evaluated and compared 
with histopathological tumour regression grade. It was concluded 
that DW-MRI was more helpful than FDG-PET/CT for the evaluation 
of therapy response [30]. 
In a prospective study, therapy response in AGC pa-
tients (n = 74) who had lesions (n = 620) with > 1 cm on CT 
were included and each lesion was also assessed with [18F]FDG 
PET. Poorly cohesive carcinomas exhibited lower SUVmax than 
adenocarcinomas. Human epidermal growth factor receptor 2 
(HER2)-positive tumours had higher SUVmax in comparison with 
HER2-negative tumours. The changes in SUVmax and total lesion 
glycolysis (TLG) owing to chemotherapy were associated with the 
changes in tumour size. Patients with a decrease in both tumour 
size and SUVmax had a better prognosis than patients who had 
only a decrease in tumour size or SUVmax [31]. 
Prediction of HER2 status
Surgery is often a part of the treatment of GC. However, 
surgery is not efficient especially for inoperable or metastatic GC 
patients. As a result of this, other therapy options are required 
for these patients [32]. Well or moderately differentiated GA, ex-
press HER2 more than poorly differentiated GA [33]. This is impor-
tant to predict HER2 status for HER2-targeted molecular therapy. 
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PET/CT plays a leading role in predicting the therapy response of 
various cancers [32]. 
Association between [18F]FDG uptake and HER2 expression 
was evaluated in 64 GC patients. SUVmax and tumour differentia-
tion was correlated with HER2 expression. When a SUVmax = 6.2 
as a cut off value was used, [18F]FDG PET/CT had 64.4% accuracy 
for predicting the HER2 expression. [18F]FDG PET/CT also might 
help predict HER-2 targeted therapy response. However, further 
prospective studies are still needed to understand its potential [32]. 
In a research study, it was found that (n = 124) HER2-positive 
GCs had higher SUVmax (median = 12.1) than HER2-negative (me-
dian = 7.4) GCs. FDG PET/CT volume-based parameters can play 
a role in both HER2-positive GCs and HER2-negative cancers for 
predicting the prognosis of AGC [34]. However, in another study 
(n = 31), that firstly compared SUVmax and HER2 status in age-
matched and sex-matched patients with GC and gastroesophageal 
junction adenocarcinomas (GEJC), SUVmax was not correlated with 
HER2 status of both cancer types. High SUVmax was correlated 
with decreased OS. Nonetheless, larger cohort studies are still 
needed to validate this result [35]. 
Conclusions
GC still has high mortality and is responsible for cancer-related 
deaths worldwide. Patients are asymptomatic at an early stage 
of GC. Early screening tests have vital importance for cancer 
patients. Unfortunately, there is no routine screening test for GC in 
daily clinical practice. On the other hand, new various screening 
biomarkers in the blood are still in progress and these studies are 
could not be applied to patients. Therefore, most of the cases di-
agnosed at the late stage which patients had an incurable disease. 
Even though diagnostic imaging modalities improved with current 
technology in this century, early and accurate detection of GC is still 
challenging for clinicians. Accurate staging and assessment of 
treatment response are important for a patient’s lifetime. PET/CT 
is a noninvasive imaging modality that is important for TNM staging 
especially for detection of distant metastasis, evaluation of thera-
py response, curability, detection of recurrent tumours. However, 
some pathological types of gastric tumours are not FDG avid and 
these tumours may not be detectable on PET/CT images. Although 
this disadvantage, PET/CT hybrid imaging method has a great 
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